Deals Of The Week: Wyeth/Santaris, Novartis/HHS, Cephalon/Ception ...
Each week, "The Pink Sheet" presents commentary on some of the week's most interesting business deals, contributed by the editors of the IN VIVO blog. Visit the blog at 1http://invivoblog.blogspot.com/.
You may also be interested in...
New top leadership at Pulmatrix, Althea and Mucosis; McKesson names Mark Walchirk president of U.S. pharma business; Former FDA Deputy Commissioner Scott Gottlieb joins Aptiv board. More personnel announcements in this month’s column.
Look for Cephalon to “roll up” more assets this year while the market is good, CEO Baldino says at J.P. Morgan.
Formerly legal adversaries, the two companies will co-develop PEG-interferon lambda, currently in Phase Ib for hepatitis C.